HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

4-methoxybenzo(a)phenazine-11-carboxylic acid (2-(dimethylamino)-1-methylethyl)amide

structure in first source

Also Known As:

XR 11576; XR-11576; XR11576

Networked: 4 relevant articles (2 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 3-Ring Heterocyclic Compounds
    - Phenazines: 42
      - 4-methoxybenzo(a)phenazine-11-carboxylic acid (2-(dimethylamino)-1-methylethyl)amide: 4

Experts

1.	Charlton, Peter A: 3 articles (02/2007 - 01/2002)
2.	Mistry, Prakash: 2 articles (02/2007 - 01/2002)
3.	Coley, Helen M: 1 article (02/2007)
4.	Lewis, Louisa J: 1 article (02/2007)
5.	Thomas, Hilary: 1 article (02/2007)
6.	Brindley, C: 1 article (10/2004)
7.	Brock, C: 1 article (10/2004)
8.	Cooper, M: 1 article (10/2004)
9.	Judson, I: 1 article (10/2004)
10.	Kaye, S: 1 article (10/2004)

Related Diseases

1.	Neoplasms (Cancer) 10/01/2004 - "These data support the rapid introduction of XR11576 to clinical trials and suggest that it may be effective against a broad spectrum of tumor types." 10/01/2004 - "Breast and gynecological malignancies were most sensitive to XR11576, while the potency of this compound was slightly attenuated in gastrointestinal tumors, in which the median IC90 and IC50 values were 308 and 212 nM, respectively. " 10/01/2004 - "Overall, the median IC90 and IC50 values of XR11576 in tumor-derived cells were 242 and 110 nM, respectively. " 10/01/2004 - "Ex vivo characterization of XR11576 (MLN576) against ovarian cancer and other solid tumors." 10/01/2004 - "XR11576 (MLN576) is a novel monophenazine with a mechanism of action that includes interaction with both topoisomerase (Topo) I and II. The aim of this study was to evaluate its cytotoxicity against fresh tumor cells taken from patients with a variety of solid tumors. "
2.	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/01/2002 - "In vivo XR11576 showed marked efficacy against a number of tumors including sensitive (H69/P) and multidrug-resistant (H69/LX4) small cell lung cancer and the relatively refractory MC26 and HT29 colon carcinomas following i.v. and p.o. "
3.	Carcinoma (Carcinomatosis) 01/01/2002 - "In vivo XR11576 showed marked efficacy against a number of tumors including sensitive (H69/P) and multidrug-resistant (H69/LX4) small cell lung cancer and the relatively refractory MC26 and HT29 colon carcinomas following i.v. and p.o. "
4.	Ovarian Neoplasms (Ovarian Cancer) 10/01/2004 - "Ex vivo characterization of XR11576 (MLN576) against ovarian cancer and other solid tumors." 02/01/2007 - "We set out to study this further using human tumour cell lines, PEO1 ovarian cancer, MDA-MB-231 breast cancer and variants with acquired resistance to VP-16 and XR11576: PEO1VPR, MB-231VPR, MB-231-11576R and camptothecin: PEO1CamR. "
5.	Fatigue 10/18/2004 - "In this study, the DLTs of XR11576 were diarrhoea and fatigue. "

Related Drugs and Biologics

1.	Enzymes
2.	Type I DNA Topoisomerases (Topoisomerase I)
3.	phenazine
4.	Etoposide (VP 16)
5.	Camptothecin
6.	trioctyl phosphine oxide (TOPO)
7.	Paclitaxel (Taxol)
8.	Doxorubicin (Adriamycin)
9.	Vinorelbine (Navelbine)